Back to Search
Start Over
Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary
- Source :
- International Journal of Clinical Oncology
- Publication Year :
- 2021
-
Abstract
- Background Tissue factor pathway inhibitor 2 (TFPI2) is a novel serum biomarker that discriminates ovarian clear cell carcinoma (CCC) from borderline ovarian tumors (BOTs) and non-clear cell epithelial ovarian cancers (EOCs). Here, we examined the performance of TFPI2 for preoperative diagnosis of CCC. Methods Serum samples were obtained preoperatively from patients with ovarian masses, who needed surgical treatment at five hospitals in Japan. The diagnostic powers of TFPI2 and cancer antigen 125 (CA125) serum levels to discriminate CCC from BOTs, other EOCs, and benign lesions were compared. Results A total of 351 patients including 69 CCCs were analyzed. Serum TFPI2 levels were significantly higher in CCC patients (mean ± SD, 508.2 ± 812.0 pg/mL) than in patients with benign lesions (154.7 ± 46.5), BOTs (181 ± 95.5) and other EOCs (265.4 ± 289.1). TFPI2 had a high diagnostic specificity for CCC (79.5%). In patients with benign ovarian endometriosis, no patient was positive for TFPI2, but 71.4% (15/21) were CA125 positive. TFPI2 showed good performance in discriminating stage II–IV CCC from BOTs and other EOCs (AUC 0.815 for TFPI2 versus 0.505 for CA125) or endometriosis (AUC 0.957 for TFPI2 versus 0.748 for CA125). The diagnostic sensitivity of TFPI2 to discriminate CCC from BOTs and other EOCs was improved from 43.5 to 71.0% when combined with CA125. Conclusions High specificity of TFPI2 for preoperative detection of CCC was verified with the defined cutoff level of TFPI2 in clinical practice. TFPI2 and CA125 may contribute substantially to precise prediction of intractable CCC.
- Subjects :
- medicine.medical_specialty
endocrine system diseases
Lipoproteins
Endometriosis
Ovary
Carcinoma, Ovarian Epithelial
Gastroenterology
TFPI2
03 medical and health sciences
CA125
0302 clinical medicine
Japan
Ovarian cancer
Internal medicine
medicine
Biomarkers, Tumor
Humans
Stage (cooking)
education
Glycoproteins
Clear cell carcinoma
Ovarian Neoplasms
education.field_of_study
030219 obstetrics & reproductive medicine
business.industry
Hematology
General Medicine
medicine.disease
Tissue-factor-pathway inhibitor 2
female genital diseases and pregnancy complications
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
CA-125 Antigen
Ovarian Endometriosis
Biomarker (medicine)
Surgery
Female
Original Article
Serum tumor marker
business
Subjects
Details
- ISSN :
- 14377772
- Volume :
- 26
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- International journal of clinical oncology
- Accession number :
- edsair.doi.dedup.....d053395af6297b9920416194bc697fda